Delivery Order SPE2DB25D3001-SPE2DB25FQTXA

Award Date 1/22/25
Potential Completion Date 1/23/25
Potential Value $4.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. for the delivery of XIFAXAN 550 mg tablets. The contract has a ceiling value of $14,731.55 and runs through July 17, 2024. The contract is a Delivery Order on a Firm Fixed Price basis, with no set-aside designation. AmerisourceBergen Drug Corp. is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal...
This federal contract award, identified as SPE2DB20D2104|SPE2DB25FMJFM, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $27,091.02 and a period of performance through February 19, 2025. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical...
This federal contract award, with ID SPE2DB22D3004|SPE2DB25FNS81, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract, valued at $25,204.50, is for the delivery of 60 tablets of the pharmaceutical product XIFAXAN 550 MG. The contract has an ultimate completion date of December 6, 2024 and is a Firm Fixed Price Delivery Order. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, for the delivery of XIFAXAN 550 MG TABLET 60S. The contract has a ceiling value of $17,572.67 and runs through May 30, 2024. It is a firm fixed-price delivery order contract with no set-aside designation. Amerisourcebergen, a major pharmaceutical distributor and healthcare solutions provider, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, with ID SPE2DB22D2006|SPE2DB25FV8EH, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $12,283.25. This is a firm fixed-price delivery order contract with a final completion date of February 6, 2025. The contract does not have a set-aside designation,...
This federal contract award, valued at $30,505.82, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with an ultimate completion date of June 25, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type, and it was awarded on June 24, 2024. The contract does not have a set-aside...
This federal contract award, identified as SPE2DB22D3301|SPE2DB24FZ1ED, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp. The contract is for the delivery of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $23,686.65 and a completion date of July 23, 2024. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation indicated. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...
This federal contract award, identified as SPE2DB25D2207|SPE2DB25FQPTH, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XIFAXAN 550 mg tablets, a pharmaceutical product, and has a ceiling value of $17,776.50. The contract is a Delivery Order with a Firm Fixed Price pricing type and an Ultimate Completion Date of October 31, 2024. It is not designated as a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide XIFAXAN 550 MG TABLET 60S, a pharmaceutical product, through March 15, 2024. The contract has a ceiling value of $3,346.90 and was not set aside for any specific business type. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,703.10 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of February 26, 2025 and was awarded on February 25, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
  • SPE2DB25D3001
    Indefinite Delivery Contract
  • SPE2DB25D3001-SPE2DB25FQTXA
    Delivery Order

The federal contract award SPE2DB25D3001|SPE2DB25FQTXA was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, for the delivery of XIFAXAN 550 mg tablets. The contract has a ceiling value of $4,141.30 and a completion date of January 23, 2025. It is a firm-fixed-price delivery order contract, without any set-aside designation.

Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies, particularly within military and veterans' healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 5/21/25, 9:50 AM